home All News open_in_new Full Article

Merakris Therapeutics Secures FDA Agreement for Type C Meeting to Advance MTX

RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) — Merakris Therapeutics, a regenerative medicine company developing biologic drug therapies for hard-to-heal wounds, today announced that it is scheduled for a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss its clinical development program and manufacturing scale-up plans for its lead […]


today 5 d. ago attach_file Other

attach_file Other
attach_file Events
attach_file Politics
attach_file Events
attach_file Other
attach_file Other
attach_file Politics
attach_file Politics
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Sport
attach_file Politics
attach_file Other
attach_file Events
attach_file Economics


ID: 3445535041
Add Watch Country

arrow_drop_down